|
Volumn 120, Issue 2, 2003, Pages
|
Assessing the safety of immunologic modifiers for the treatment of chronic disease: The psoriasis paradigm
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOSPORIN;
IMMUNOMODULATING AGENT;
IMMUNOSUPPRESSIVE AGENT;
IMMUNOLOGICAL ADJUVANT;
CANCER INCIDENCE;
CANCER RISK;
CHRONIC DISEASE;
DRUG SAFETY;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
NOTE;
PRIORITY JOURNAL;
PSORIASIS;
PUVA;
SKIN CANCER;
SKIN DISEASE;
SQUAMOUS CELL CARCINOMA;
IMMUNOLOGY;
ADJUVANTS, IMMUNOLOGIC;
CHRONIC DISEASE;
HUMANS;
PSORIASIS;
|
EID: 0037289796
PISSN: 0022202X
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1523-1747.2003.120022.x Document Type: Editorial |
Times cited : (9)
|
References (11)
|